IL4I1 Antibody

What is IL4I1 and why is it significant in immunological research?

Interleukin-4 Induced Gene 1 (IL4I1) is a secreted L-phenylalanine oxidase primarily produced by inflammatory antigen-presenting cells, particularly macrophages present in T helper type 1 granulomas and various tumor types. IL4I1 has significant immunological importance as it is involved in:

• Fine control of B- and T-cell adaptive immune responses

• Cancer immune evasion mechanisms

• Regulation of inflammatory responses

• Oxidative deamination of aromatic amino acids, particularly phenylalanine

The protein belongs to the flavin monoamine oxidase family, FIG1 subfamily, and has L-amino acid oxidase activity with preference toward aromatic amino acids . Recent research has identified IL4I1 as a novel potential target for cancer treatment due to its role in promoting aryl hydrocarbon receptor (AHR)-driven malignant properties and suppressing anti-tumor immunity .

What are the optimal applications for IL4I1 antibodies in research?

IL4I1 antibodies have been validated for several key applications in research settings:

When selecting an application, consider that IL4I1 has been successfully detected in various samples including HeLa cells, Jurkat cells, mouse liver tissue, and THP-1 human acute monocytic leukemia cell lines treated with PMA and LPS . For visualizing IL4I1 in cellular contexts, immunofluorescence has been effective in identifying its localization in the cytoplasm, particularly in lysosomes, as demonstrated in HDLM-2 human Hodgkin's lymphoma cell lines .

How do I select the appropriate IL4I1 antibody for my experiment?

Selecting the appropriate IL4I1 antibody requires consideration of several factors:

• Target Species Reactivity: Confirm the antibody has been validated for your species of interest. Common reactive species include human and mouse .

• Epitope Recognition: Consider which region of IL4I1 the antibody recognizes. Options include:

  • Full-length protein antibodies (Met1-His567)

  • C-terminal region-specific antibodies

  • Specific amino acid region antibodies (e.g., aa 486-535)

• Clone Type: Decide between:

  • Monoclonal antibodies (e.g., clone #1006202) for high specificity

  • Polyclonal antibodies for broader epitope recognition

• Validated Applications: Ensure the antibody has been validated for your specific application with published evidence .

• Isotype and Host: Consider the host animal (commonly rabbit) and isotype (e.g., IgG) for potential secondary antibody compatibility .

Always review validation data galleries and literature citations before making your selection to ensure optimal performance in your experimental system.

What are the recommended protocols for detecting IL4I1 in cell culture systems?

For effective detection of IL4I1 in cell culture systems, consider these methodology recommendations:

Cell Lines with Confirmed IL4I1 Expression:

• THP-1 cells (human acute monocytic leukemia) treated with 200 nM PMA for 24 hours and 10 μg/mL LPS for 3 hours

• HDLM-2 human Hodgkin's lymphoma cell line

• HeLa cells

• Jurkat cells

Western Blot Protocol:

• Lyse cells in appropriate buffer containing protease inhibitors

• Separate proteins using SDS-PAGE

• Transfer to PVDF membrane

• Block with appropriate blocking buffer

• Probe with IL4I1 antibody at 1:500-1:2000 dilution

• Incubate with HRP-conjugated secondary antibody

• Develop using chemiluminescent substrate

• Expected molecular weight: approximately 70-75 kDa (calculated: 63 kDa)

Immunofluorescence Protocol:

• Fix cells (immersion fixation recommended)

• Permeabilize cell membrane

• Block non-specific binding

• Incubate with IL4I1 antibody (1:200-1:800)

• Add fluorophore-conjugated secondary antibody

• Counterstain with DAPI for nuclear visualization

• Expected localization: cytoplasm, particularly in lysosomes

These protocols should be optimized for your specific experimental conditions and cell types.

How can I utilize IL4I1 antibodies to study immunosuppressive mechanisms in cancer?

IL4I1 antibodies are valuable tools for investigating cancer immunosuppression through several methodological approaches:

Tumor Microenvironment Analysis:

• Use IL4I1 antibodies for immunohistochemistry on tumor tissue sections to identify IL4I1-expressing cells within the tumor microenvironment

• Co-stain with markers for tumor-associated macrophages (TAMs) such as CD68 to establish correlation between IL4I1 expression and TAM infiltration

• Implement multiplex immunofluorescence to simultaneously detect IL4I1, immune cell markers, and AHR pathway components

Functional Studies:

• Use IL4I1 antibodies to confirm knockdown efficiency when establishing IL4I1-shRNA models to study loss-of-function effects

• Implement IL4I1 antibodies in Western blot analysis to compare IL4I1 expression in:

  • Tumor cells overexpressing IL4I1 versus controls

  • Samples before and after immune checkpoint inhibitor treatment

Mechanistic Investigations:

• Employ IL4I1 antibodies to immunoprecipitate IL4I1 protein complexes to identify interaction partners

• Use IL4I1 antibodies to track changes in IL4I1 expression following treatments with:

  • Anti-PD-1/PD-L1 antibodies

  • IDO1 inhibitors

  • AHR pathway modulators

Research has shown that IL4I1-overexpressing tumors show resistance to anti-PD-L1 antibody therapy and exhibit altered lymphoid cell subsets with significant suppression of cytotoxic T cell infiltration . These methodologies can help elucidate the mechanisms behind these observations.

What are the best practices for interpreting IL4I1 antibody staining in tissue sections?

When interpreting IL4I1 antibody staining in tissue sections, consider these best practices:

Staining Pattern Interpretation:

• IL4I1 typically shows cytoplasmic localization in lymphocytes and macrophages

• In B cell lymphomas, specific staining has been observed in the cytoplasm of lymphocytes

• In tumor tissues, pay attention to both tumor cells and infiltrating immune cells, as both can express IL4I1

Controls and Validation:

• Always include positive controls:

  • B cell lymphoma tissues have demonstrated reliable IL4I1 staining

  • Lymphoid tissues with T helper type 1 granulomas

• Include negative controls:

  • Isotype control antibodies

  • Tissues known to be negative for IL4I1 expression

• Consider antigen retrieval optimization:

  • Heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic has been effective for IL4I1 detection

Quantification Approaches:

• Semi-quantitative scoring:

  • 0 (negative), 1+ (weak), 2+ (moderate), 3+ (strong)

  • Record percentage of positive cells along with intensity

• Digital image analysis:

  • Use appropriate software to quantify staining intensity

  • Distinguish between different cell populations if performing multiplex staining

Interpretation Challenges:

• Be aware that IL4I1 expression can vary based on inflammatory status of the tissue

• Consider that IL4I1 is inducible by various stimuli including IL-4 and inflammatory signals

• Correlate IHC findings with other methods (e.g., Western blot, RNA expression) when possible

How can IL4I1 antibodies be used to investigate the relationship between IL4I1 and the aryl hydrocarbon receptor (AHR) pathway?

IL4I1 antibodies can be strategically employed to investigate the IL4I1-AHR axis through several advanced methodological approaches:

Co-localization Studies:

• Perform dual immunofluorescence staining with IL4I1 and AHR antibodies

• Analyze subcellular localization changes of AHR following IL4I1 expression or inhibition

• Track nuclear translocation of AHR in response to IL4I1-produced metabolites

Metabolite-Mediated AHR Activation:

• Use IL4I1 antibodies to confirm IL4I1 expression levels when investigating how IL4I1-derived metabolites (phenylpyruvic acid, indole-3-pyruvic acid, indole-3-aldehyde) activate AHR

• Implement chromatin immunoprecipitation (ChIP) assays using AHR antibodies after confirming IL4I1 expression to identify AHR target genes activated in response to IL4I1 activity

Signaling Pathway Analysis:

• Use IL4I1 antibodies in Western blots to confirm IL4I1 levels when studying:

  • AHR target gene expression changes (CYP1B1, AKR1C1, SLC7A11)

  • Hierarchical activation of gene transcriptional signatures linked to cell protective networks

• Implement IL4I1 antibodies in proximity ligation assays to investigate potential physical interactions between IL4I1 and components of the AHR signaling pathway

Research has demonstrated that IL4I1-derived metabolites, particularly indole-3-pyruvic acid (I3P) and indole-3-aldehyde (I3A), activate AHR signaling through receptor-ligand binding, leading to increased cancer cell motility and diminished proliferation of cytotoxic CD8+ T cells . Additionally, these metabolites induce hierarchical activation of a gene transcriptional signature linked to cell protective genes .

What methodologies can be employed to study IL4I1's role in tryptophan metabolism using specific antibodies?

To investigate IL4I1's role in tryptophan metabolism, researchers can employ these advanced methodological approaches using IL4I1 antibodies:

Metabolic Profiling with Antibody Validation:

• Use IL4I1 antibodies to confirm IL4I1 expression/knockdown in experimental models

• Employ mass spectrometry to quantify tryptophan metabolites (I3P, I3A) in:

  • Cell culture supernatants from IL4I1-expressing versus IL4I1-knockdown cells

  • Tissue samples with varying IL4I1 expression levels

• Correlate metabolite levels with IL4I1 protein expression as quantified by Western blot

Functional Studies with Enzymatic Activity Correlation:

• Use recombinant IL4I1 in enzymatic assays with tryptophan as substrate

• Confirm enzyme purity and identity using IL4I1 antibodies

• Analyze reaction products (I3P, I3A) and correlate with enzymatic activity

• Implement IL4I1 antibodies in immunoprecipitation to pull down native enzyme for activity assays

In vivo Analysis of IL4I1-Mediated Tryptophan Metabolism:

• Generate IL4I1 knockdown models using lentiviral shRNA approaches

  • Target sequence example: 5'-GCAACTATGTGGTGGAGAAGG-3'

• Validate knockdown efficiency using IL4I1 antibodies via Western blot

• Compare tryptophan metabolite profiles in tissues from:

  • Wild-type animals

  • IL4I1 knockdown animals

  • Animals treated with IL4I1 inhibitors

Research has shown that IL4I1-catalyzed tryptophan metabolites, particularly I3P and I3A, play crucial roles in:

• Inhibiting neutrophil infiltration through AHR-driven TSG-6 expression

• Weakening pathogenic phenotypes of neutrophils in damaged lungs

• Mediating immunosuppressive functions in muscle stem cells (MuSCs)

How can I utilize IL4I1 antibodies to study resistance mechanisms to immune checkpoint inhibitors?

To investigate IL4I1's role in resistance to immune checkpoint inhibitors (ICIs), implement these methodological approaches using IL4I1 antibodies:

Temporal Expression Analysis:

• Use IL4I1 antibodies in Western blot or IHC to monitor IL4I1 expression:

  • Before ICI treatment

  • During treatment

  • At progression/resistance development

• Correlate IL4I1 expression with clinical response to anti-PD-1/PD-L1 antibodies

Mechanistic Studies in Experimental Models:

• Establish IL4I1-overexpressing tumor models:

  • Use IL4I1 antibodies to confirm overexpression in different cell lines

  • Compare response to ICIs between IL4I1-overexpressing and control tumors

• Implement IL4I1 knockdown/knockout approaches:

  • Use CRISPR/Cas9 or shRNA technology

  • Validate using IL4I1 antibodies

  • Assess sensitivity to ICIs with/without IL4I1 expression

Immune Microenvironment Characterization:

• Perform multiplex immunofluorescence with IL4I1 antibodies and markers for:

  • Cytotoxic T cells (CD8)

  • Tumor-associated macrophages (CD68)

  • Other immunosuppressive cells

• Quantify changes in immune cell populations in relation to IL4I1 expression and ICI treatment

Combined Inhibition Strategies:

• Use IL4I1 antibodies to monitor IL4I1 expression when combining:

  • ICIs (anti-PD-1/PD-L1)

  • IDO1 inhibitors

  • Potential IL4I1 inhibitors

• Correlate IL4I1 expression with AHR activation status and treatment response

Research has demonstrated that IL4I1-overexpressing tumors show resistance to anti-PD-L1 antibody therapy. Transcriptome analysis revealed immunosuppressive genes were globally upregulated in IL4I1-overexpressing tumors, with significant suppression of cytotoxic T cell infiltration. Additionally, anti-PD1 monoclonal antibody treatment increased IL4I1 and IDO1 expression, resulting in AHR activation, potentially explaining why IDO1 inhibitors failed in combination with anti-PD1 therapy .

What are the common challenges when using IL4I1 antibodies and how can they be addressed?

Researchers may encounter several challenges when working with IL4I1 antibodies. Here are common issues and recommended solutions:

Specificity Concerns:

• Issue: Cross-reactivity with related proteins
  Solution:

  • Validate antibody specificity using IL4I1 knockdown controls

  • Compare multiple antibody clones targeting different epitopes

  • Perform peptide competition assays to confirm specificity

Detection Sensitivity:

• Issue: Weak signal in Western blot
  Solution:

  • Optimize protein loading (60-75 kDa expected band size)

  • Consider enhanced chemiluminescence substrates

  • Increase antibody concentration (up to 1:500 dilution)

  • Use PVDF membrane instead of nitrocellulose

• Issue: Poor signal in immunofluorescence
  Solution:

  • Optimize fixation method (immersion fixation recommended)

  • Implement heat-induced epitope retrieval

  • Increase antibody concentration (up to 1:200 dilution)

  • Consider signal amplification systems

Background Issues:

• Issue: High background in immunohistochemistry
  Solution:

  • Optimize blocking conditions (use 5% BSA or commercial blocking reagents)

  • Titrate primary antibody concentration

  • Increase washing steps duration and number

  • Consider using HRP polymer detection systems instead of ABC methods

Variable Expression Levels:

• Issue: Inconsistent IL4I1 detection across samples
  Solution:

  • Remember IL4I1 is inducible - standardize culture conditions

  • For cell lines, consider treatment with PMA (200 nM, 24h) and LPS (10 μg/mL, 3h) to induce expression

  • Include positive controls (e.g., THP-1 cells with PMA/LPS treatment, B cell lymphoma samples)

Storage and Handling:

• Issue: Antibody performance degradation
  Solution:

  • Store at -20°C as recommended

  • Aliquot to avoid freeze-thaw cycles

  • Use glycerol-containing storage buffer (e.g., PBS with 0.02% sodium azide and 50% glycerol, pH 7.3)

How can I quantitatively analyze IL4I1 expression data from different experimental approaches?

For robust quantitative analysis of IL4I1 expression data, consider these methodological approaches:

Western Blot Quantification:

• Densitometric analysis:

  • Use software like ImageJ, Image Lab, or LI-COR systems

  • Normalize IL4I1 band intensity to loading controls (β-actin, GAPDH)

  • Express as fold-change relative to control samples

• Statistical considerations:

  • Perform at least three independent biological replicates

  • Use appropriate statistical tests (t-test, ANOVA) based on experimental design

  • Report means ± standard deviation/SEM

Immunohistochemistry/Immunofluorescence Quantification:

• Semi-quantitative scoring:

  • Implement H-score method: H-score = Σ(Pi × i), where Pi = percentage of cells with intensity i (0-3)

  • Alternatively, use Allred scoring combining proportion and intensity

• Digital image analysis:

  • Use software like QuPath, ImageJ, or commercial platforms

  • Implement machine learning algorithms for cell classification

  • Quantify parameters like:

    • Percentage of IL4I1-positive cells

    • Mean fluorescence/staining intensity

    • Subcellular localization patterns

Correlation with Clinical/Experimental Outcomes:

• Survival analysis:

  • Stratify samples by IL4I1 expression levels (low vs. high)

  • Generate Kaplan-Meier curves

  • Calculate hazard ratios and p-values using log-rank tests

• Correlation with experimental variables:

  • Use Pearson's or Spearman's correlation to assess relationships between:

    • IL4I1 expression and immune cell infiltration

    • IL4I1 expression and response to treatments

    • IL4I1 expression and AHR target gene expression

Research has shown that IL4I1 expression correlates with poor prognosis in various cancer types and is associated with reduced infiltration of cytotoxic T cells and enhanced tumor-associated macrophage markers like CD68 . Implementing these quantitative approaches will help establish similar correlations in your experimental system.

What alternative approaches can complement IL4I1 antibody-based detection methods?

To comprehensively study IL4I1 biology, consider these complementary approaches that extend beyond antibody-based detection:

Genetic Manipulation Techniques:

• CRISPR/Cas9 gene editing:

  • Generate IL4I1 knockout cell lines/animal models

  • Create IL4I1 reporter systems (e.g., GFP fusion)

  • Validate using antibody-based methods

• RNA interference:

  • Implement shRNA approaches targeting IL4I1

  • Example target sequence: 5'-GCAACTATGTGGTGGAGAAGG-3'

  • Validate knockdown efficiency with both antibody and mRNA detection methods

Metabolite Analysis:

• Mass spectrometry:

  • Quantify IL4I1-catalyzed metabolites (PP, I3P, I3A)

  • Compare metabolite profiles between:

    • Wild-type vs. IL4I1-manipulated models

    • Treated vs. untreated conditions

• Enzymatic activity assays:

  • Measure IL4I1 L-amino acid oxidase activity using:

    • Colorimetric hydrogen peroxide detection

    • Fluorometric detection of reaction products

  • Correlate activity with protein expression levels determined by antibodies

Transcriptomic Approaches:

• RNA-seq analysis:

  • Compare gene expression profiles in:

    • IL4I1-high vs. IL4I1-low tissues/cells

    • Before vs. after IL4I1 manipulation

  • Focus on AHR target genes and immunoregulatory pathways

• Single-cell RNA-seq:

  • Identify cell populations expressing IL4I1

  • Characterize the transcriptional landscape of IL4I1-expressing cells

  • Correlate with protein-level detection using antibodies

Functional Assays:

• T-cell proliferation assays:

  • Assess inhibitory effects of IL4I1-expressing cells or recombinant IL4I1

  • Compare IL4I1-wildtype vs. mutant/inactive versions

  • Validate IL4I1 expression using antibody-based methods

• Migration/invasion assays:

  • Evaluate effects of IL4I1 expression on cancer cell motility

  • Correlate with AHR activation status

  • Validate protein expression using IL4I1 antibodies

These complementary approaches provide a comprehensive understanding of IL4I1 biology beyond what can be achieved with antibody-based detection alone, while still utilizing antibodies for validation and correlation studies.